Intensive Care Network Podcasts

Sinopsis

Critical Care podcasts from the Intensive Care Network

Episodios

  • Thromboembolism

    Thromboembolism

    13/08/2019 Duración: 24min

    Associate Professor Samuel Galvagno: Thromboembolism. From CICM ASM PROGRAM 2019.  

  • Tranexamic Acid

    Tranexamic Acid

    11/08/2019 Duración: 18min

    Professor Stephen Bernard: Tranexamic Acid. From CICM ASM PROGRAM 2019.  

  • Erythropoietin  other inflammatory modulators

    Erythropoietin & other inflammatory modulators

    09/08/2019 Duración: 19min

    Associate Professor Craig French: Erythropoietin & other inflammatory modulators. From CICM ASM PROGRAM 2019. Supported by Donate Life

  • Trauma by Remote

    Trauma by Remote

    08/08/2019 Duración: 23min

    Professor Chad Ball: Trauma by Remote. From CICM ASM PROGRAM 2019

  • Remote Trauma

    Remote Trauma

    07/08/2019 Duración: 31min

    Dr John O’Neill: Remote Trauma. From CICM ASM PROGRAM 2019

  • Why do we need a NCCTRC?

    Why do we need a NCCTRC?

    06/08/2019 Duración: 22min

    Associate Professor Dianne Stephens: Why do we need a NCCTRC? From CICM ASM PROGRAM 2019  

  • Anything a Hospital Can Do I Can Do First.

    Anything a Hospital Can Do; I Can Do First.

    05/08/2019 Duración: 18min

    Dr. Stephen Rashford: Anything a Hospital Can Do; I Can Do First. From CICM ASM PROGRAM 2019

  • FELICITY HAWKER PAPER PRESENTATIONS

    FELICITY HAWKER PAPER PRESENTATIONS

    04/08/2019 Duración: 59min

    SESSION 3 FELICITY HAWKER PAPER PRESENTATIONS Chairs: Dr Matthew Maiden & Dr Raj Goud From CICM ASM PROGRAM 2019  

  • Debate: Goal directed vs Ratio-based Transfusion

    Debate: Goal directed vs Ratio-based Transfusion

    03/08/2019 Duración: 22min

    Dr Nicola Curry & Dr James Winearls: Debate: Goal directed vs Ratio-based Transfusion. From CICM ASM PROGRAM 2019

  • Innovations in Transfusion

    Innovations in Transfusion

    02/08/2019 Duración: 21min

    Dr. Zoe McQuilten: Innovations in transfusion. From CICM ASM PROGRAM 2019

  • ECMO

    ECMO

    01/08/2019 Duración: 28min

    Associate Professor Samuel Galvagno: ECMO. From CICM ASM PROGRAM 2019

  • REBOA

    REBOA

    31/07/2019 Duración: 23min

    Professor Mark Midwinter: REBOA. From CICM ASM PROGRAM 2019

  • RAPTOR

    RAPTOR

    30/07/2019 Duración: 29min

    Professor Chad Ball: RAPTOR. From CICM ASM PROGRAM 2019  

  • Delirium and Withdrawal in the Paediatric ICU

    Delirium and Withdrawal in the Paediatric ICU

    29/07/2019 Duración: 17min

    A Podcast by Shree Basu and Corrine Balit

  • Managing Analgesia and Sedation in Paediatric ICU

    Managing Analgesia and Sedation in Paediatric ICU

    29/07/2019 Duración: 33min

    A Podcast by Shree Basu and Corrine Balit

  • Post Resus Care in Paediatric ICU

    Post Resus Care in Paediatric ICU

    29/07/2019 Duración: 36min

    A podcast by two intensivists from Westmead PICU on post resuscitation care.

  • CHRISTCHURCH: What happened, what we did and how we did it…

    CHRISTCHURCH: What happened, what we did and how we did it…

    24/07/2019 Duración: 43min

    CHRISTCHURCH Chair: Dr Ray Raper Dr James Mckay: What happened, what we did and how we did it… Dr Louise Hitchings: What we learned, and what we would like you to know. From CICM ASM PROGRAM 2019.  

  • Immune diseases - What about all those MABs

    Immune diseases - What about all those MABs

    10/10/2018 Duración: 28min

    Monoclonal antibodies (MAbs), guided by molecular studies and personalised medicine are changing the face of clinical medicine.  They hold the promise of controlling diseases and improving survival whilst reducing the side effects of some ‘traditional’ therapies. MAbs are being used in conditions familiar to intensivists such as asthma, invasive candidiasis, RSV infection, reversal of novel anticoagulants and clostridium difficile infection as well as in those less commonly seen by intensivists such as multiple sclerosis, migraine, rheumatoid arthritis and numerous malignancies. Side effects of MAb treatment pose particular challenges for intensivists and range from cytokine release syndrome to autoimmune states (such as colitis, endocrinopathies, skin reactions), pneumonitis, thromboemboli, and infections. Pharmcokinetic interactions of MAbs with other drugs remain poorly studied and may be immune dependent, cytokine dependent or target dependent. Our traditional approach of triaging patients for ICU, based

  • Malignancy

    Malignancy

    10/10/2018 Duración: 26min

    The incidence of cancer is increasing in line with our ageing population, with a greater number of patients requiring ICU admission for support managing complications of their malignancy, it’s therapy, or conditions unrelated to their underlying cancer. Despite these indications, the presence of a cancer diagnosis has been a common reason for refusal of ICU admission, or admission with treatment limitations.   This session will present the current epidemiology, characteristics and outcomes of patients admitted to Australian and New Zealand Intensive Care Units with cancer, and will describe the change in these outcomes across the last 17 years. Results will be reported for the most common malignancies admitted to ANZ intensive care units, common treatments and complications of malignancy will be reviewed and an agenda for further outcomes research in ICU malignancy will be proposed, with demonstration of early work in the analysis of outcomes relating to specific types of malignancy.

  • Massive Stroke

    Massive Stroke

    10/10/2018 Duración: 21min

    There have been significant developments in the diagnosis and management of ischaemic stroke.   This started with trials showing a benefit for decompressive craniectomy after a malignant hemispheric stroke in patients under 60 undergoing surgery within 48 hours.   The evolution of CT and MRI have enabled us to better image not only the ischaemic core of the stroke, but also the surrounding hypo-perfused brain at risk of ischaemic death; the penumbra. CT and MR angiography now allow rapid, non-invasive detection of occlusions in the major neck and intracranial arterial vessels.  These techniques are key to the appropriate selection of patients for therapeutic interventions aiming at rapid and effective arterial recanalisation to restore blood flow. Intravenous thrombolysis with rt-PA is effective if given early and no later than 4.5 hours. The benefit of intravenous thrombolysis for patients with severe stroke due to large artery occlusion is limited but these patients may be candidates for mechanical thrombec

página 3 de 22

Informações: